Kristina Meyer

Kristina Meyer brings more than 15 years of commercial and business development experience in the biotech industry. Kristina joined Inventiva in 2015 from Oxford BioTherapeutics where she was responsible for the outlicensing of pre-clinical oncology assets, inlicensing of antibody arming technologies, oncology target discovery collaborations and alliance management. Prior to Oxford BioTherapeutics she worked at Evotec in the USA and the UK where she had regional commercial responsibility for the discovery alliance business across various therapeutic areas and territories. Dr. Meyer holds a PhD. in organic chemistry from the University of Frankfurt, Germany, and conducted post-doctoral research at Yale University in New Haven, CT, USA.